These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 26881291)
1. Correlation of in Situ Oxazolidine Formation with Highly Synergistic Cytotoxicity and DNA Cross-Linking in Cancer Cells from Combinations of Doxorubicin and Formaldehyde. Barthel BL; Mooz EL; Wiener LE; Koch GG; Koch TH J Med Chem; 2016 Mar; 59(5):2205-21. PubMed ID: 26881291 [TBL] [Abstract][Full Text] [Related]
2. Doxazolidine, a proposed active metabolite of doxorubicin that cross-links DNA. Post GC; Barthel BL; Burkhart DJ; Hagadorn JR; Koch TH J Med Chem; 2005 Dec; 48(24):7648-57. PubMed ID: 16302805 [TBL] [Abstract][Full Text] [Related]
3. Formaldehyde-releasing prodrugs in combination with adriamycin can overcome cellular drug resistance. Cutts SM; Nudelman A; Pillay V; Spencer DM; Levovich I; Rephaeli A; Phillips DR Oncol Res; 2005; 15(4):199-213. PubMed ID: 17822280 [TBL] [Abstract][Full Text] [Related]
4. Activation of clinically used anthracyclines by the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate. Cutts SM; Swift LP; Pillay V; Forrest RA; Nudelman A; Rephaeli A; Phillips DR Mol Cancer Ther; 2007 Apr; 6(4):1450-9. PubMed ID: 17431124 [TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and preliminary evaluation of doxazolidine carbamates as prodrugs activated by carboxylesterases. Burkhart DJ; Barthel BL; Post GC; Kalet BT; Nafie JW; Shoemaker RK; Koch TH J Med Chem; 2006 Nov; 49(24):7002-12. PubMed ID: 17125253 [TBL] [Abstract][Full Text] [Related]
6. Nuclear targeting and nuclear retention of anthracycline-formaldehyde conjugates implicates DNA covalent bonding in the cytotoxic mechanism of anthracyclines. Taatjes DJ; Fenick DJ; Koch TH Chem Res Toxicol; 1999 Jul; 12(7):588-96. PubMed ID: 10409398 [TBL] [Abstract][Full Text] [Related]
7. A dual-targeting hybrid platinum(IV) prodrug for enhancing efficacy. Xiao H; Yan L; Zhang Y; Qi R; Li W; Wang R; Liu S; Huang Y; Li Y; Jing X Chem Commun (Camb); 2012 Nov; 48(87):10730-2. PubMed ID: 23012698 [TBL] [Abstract][Full Text] [Related]
8. Reduction-Responsive Chemo-Capsule-Based Prodrug Nanogel for Synergistic Treatment of Tumor Chemotherapy. Lu Y; Jia D; Ma X; Liang M; Hou S; Qiu W; Gao Y; Xue P; Kang Y; Xu Z ACS Appl Mater Interfaces; 2021 Feb; 13(7):8940-8951. PubMed ID: 33565847 [TBL] [Abstract][Full Text] [Related]
9. Doxoform and Daunoform: anthracycline-formaldehyde conjugates toxic to resistant tumor cells. Fenick DJ; Taatjes DJ; Koch TH J Med Chem; 1997 Aug; 40(16):2452-61. PubMed ID: 9258351 [TBL] [Abstract][Full Text] [Related]
10. Self-assembling doxorubicin-tocopherol succinate prodrug as a new drug delivery system: synthesis, characterization, and in vitro and in vivo anticancer activity. Duhem N; Danhier F; Pourcelle V; Schumers JM; Bertrand O; Leduff CS; Hoeppener S; Schubert US; Gohy JF; Marchand-Brynaert J; Préat V Bioconjug Chem; 2014 Jan; 25(1):72-81. PubMed ID: 24328289 [TBL] [Abstract][Full Text] [Related]
11. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy. Garsky VM; Lumma PK; Feng DM; Wai J; Ramjit HG; Sardana MK; Oliff A; Jones RE; DeFeo-Jones D; Freidinger RM J Med Chem; 2001 Nov; 44(24):4216-24. PubMed ID: 11708923 [TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of doxorubicin-formaldehyde conjugates targeted to breast cancer cells. Burke PJ; Koch TH J Med Chem; 2004 Feb; 47(5):1193-206. PubMed ID: 14971899 [TBL] [Abstract][Full Text] [Related]
14. Synthesis of pH-responsive chitosan nanocapsules for the controlled delivery of doxorubicin. Chen CK; Wang Q; Jones CH; Yu Y; Zhang H; Law WC; Lai CK; Zeng Q; Prasad PN; Pfeifer BA; Cheng C Langmuir; 2014 Apr; 30(14):4111-9. PubMed ID: 24665861 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and characterization of a photoresponsive doxorubicin/combretastatin A4 hybrid prodrug. Liu W; Liang L; Zhao L; Tan H; Wu J; Qin Q; Gou X; Sun X Bioorg Med Chem Lett; 2019 Feb; 29(3):487-490. PubMed ID: 30553736 [TBL] [Abstract][Full Text] [Related]
16. Preparation of a camptothecin prodrug with glutathione-responsive disulfide linker for anticancer drug delivery. Xu Z; Wang D; Xu S; Liu X; Zhang X; Zhang H Chem Asian J; 2014 Jan; 9(1):199-205. PubMed ID: 24136878 [TBL] [Abstract][Full Text] [Related]
17. Structural requirements for the formation of anthracycline-DNA adducts. Cutts SM; Parker BS; Swift LP; Kimura KI; Phillips DR Anticancer Drug Des; 2000 Oct; 15(5):373-86. PubMed ID: 11354313 [TBL] [Abstract][Full Text] [Related]
18. Analogues of DNA minor groove cross-linking agents incorporating aminoCBI, an amino derivative of the duocarmycins: Synthesis, cytotoxicity, and potential as payloads for antibody-drug conjugates. Giddens AC; Lee HH; Lu GL; Miller CK; Guo J; Lewis Phillips GD; Pillow TH; Tercel M Bioorg Med Chem; 2016 Nov; 24(22):6075-6081. PubMed ID: 27745990 [TBL] [Abstract][Full Text] [Related]
19. Epidoxoform: a hydrolytically more stable anthracycline-formaldehyde conjugate toxic to resistant tumor cells. Taatjes DJ; Fenick DJ; Koch TH J Med Chem; 1998 Apr; 41(8):1306-14. PubMed ID: 9548820 [TBL] [Abstract][Full Text] [Related]
20. Novel peptide-doxorubucin conjugates for targeting breast cancer cells including the multidrug resistant cells. Soudy R; Chen C; Kaur K J Med Chem; 2013 Oct; 56(19):7564-73. PubMed ID: 24028446 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]